poeder voor oplossing voor infusie

DRUG4 trials

Sponsors

University Hospital Maastricht, Amsterdam UMC, Itb-Med AB, Radboud universitair medisch centrum Stichting

Conditions

Chronic pulmonary aspergillosisHeart failure with preserved ejection fractionRenal TransplantationUnequivocal epicardial and/or microvascular vasospastic angina

Phase 1

Nebulised lIposomal aMphotericin B in chronic pUlmonary aSpergillosis: a deposition study

Not yet recruitingCTIS2025-521770-34-00

Radboud universitair medisch centrum StichtingChronic pulmonary aspergillosis

Target: 18Updated: 2025-09-04

Phase 2

Vericiguat in Vasospastic Angina (ViVA)

RecruitingCTIS2022-502998-42-00

Amsterdam UMCUnequivocal epicardial and/or microvascular vasospastic angina

Start: 2025-02-10Target: 55Updated: 2026-01-21

A 12-Month, Randomized, Controlled, Open-Label, Dose Escalation Study Evaluating Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Anti-CD2 Monoclonal Antibody, TCD601(siplizumab) Compared to Anti-Thymocyte Globulin (rATG), as Induction Therapy in de novo Renal Transplant Recipients

CompletedCTIS2023-507895-36-00

Itb-Med ABRenal Transplantation

Start: 2021-06-06End: 2024-12-11Target: 33Updated: 2024-08-02

Phase 4

The effect of empagliflozin on peripheral microvascular dysfunction in heart failure with preserved ejection fraction

CompletedCTIS2022-501682-45-00

University Hospital MaastrichtHeart failure with preserved ejection fraction

Start: 2023-02-13End: 2024-12-01Target: 48Updated: 2022-12-01